// App-Quantinova.ai

2547 : A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).

Researchers

Presenter

  • Michael J Demeure

Principal Investigators

  • Tannaz Armaghany

  • Samuel Ejadi

  • Ramesh K. Ramanathan

  • Aymen Elfiky

  • Jonathan R. Strosberg

  • David C. Smith

  • Timothy Whitsett

  • Winnie S. Liang

  • Shobana Sekar

  • John D. Carpten

  • Paul Fredlund

  • Demi Niforos

  • Andrew Dye

  • Sarabjit Gahir

  • Sean C. Semple

  • Mark Marion Kowalski

Medical Centers

  • Ashion Analytics, LLC, Phoenix, AZ

  • Westchase Oncology Center, Houston, TX

  • Virginia G. Piper Cancer Center, TGen, Scottsdale, AZ

  • Mayo Clinic Cancer Center, Scottsdale, AZ

  • Dana-Farber Cancer Institute, Boston, MA

  • Moffitt Cancer Center, Tampa, FL

  • University of Michigan, Ann Arbor, MI

  • Translational Genomics Research Institute, Phoenix, AZ

  • Arbutus Biopharma Corporation, Burnaby, BC, Canada

Locations

  • United States

  • Canada

Companies

  • Arbutus Biopharma Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Adrenal carcinoma

Biomarkers

  • Acetyl-CoA carboxylase

Drug/Treatment

  • TKM-080301

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01262235

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved